FastCompany writes about Biocogniv's cloud-based automation platform for labs

a NEW ERA FOR healthcare

The Real-Time Intelligence Platform for Labs

Hospitals and laboratories face an unprecedented human resources challenge, marked by understaffed departments and overworked providers. Biocogniv enables these critical healthcare facilities to leverage their existing electronic infrastructure and laboratory data to enhance the work of their providers with real-time, intelligent insights ranging from lab test interpretations to AI-powered diagnostic predictions.

our solutions

Meet interpAssist™, our award-winning automation solution for labs

Biocogniv interpAssist™ is a rules-based software system that enables automated, efficient, and customized clinical interpretations of complex laboratory tests, freeing up laboratory staff to work on higher yield tasks and enabling understaffed laboratories to capture otherwise lost RVUs.

From coagulation panels to opiod toxicology and COVID-19, Biocogniv offers a broad menu of interpretations that can also be customized to your laboratory needs.

Learn how UTMB, a 1,000-bed hospital system in Texas, received a national award enabled by interpAssist™

1 Million+
patients served

Stay ahead of acute conditions with aiMarkers™

Each year, over 700,000 patients die in US hospitals, and 1 in 20 of those deaths are due to late diagnosis and intervention of acute conditions. With Biocogniv's state-of-the-art digital biomarkers – aiMarkers – frontline providers can recognize and avert these acute conditions before they become irreversible.

Our pipeline of aiMarkers includes predictors for time-critical conditions like Sepsis, Acute Kidney Injury (AKI), Acute Heart Failure (AHF), and many others. Each aiMarker goes through extensive clinical validation and peer-review to ensure they meet the most rigorous medical standards.



"COVID-19 was a time of immense change both clinically and operationally. With Biocogniv’s automation platform interpAssist, we were able to scale interpretation and guidance for COVID and coordinate everyone during this time of unprecedented uncertainty. Thanks to the results we achieved with COVID, UTMB has expanded its use of interpAssist and is impressed with the results."

Peter McCaffrey, MD FCAP

Director, Lab Information Services
Director, Pathology Informatics
University of Texas Medical Branch (UTMB)


"I oversee innovation at an organization that employs 5,000 frontline providers at hundreds of hospitals, so we've seen many products. I believe Biocogniv's aiMarkers are a breakthrough in medicine as they go beyond traditional alerts that merely point out what can be known without them – it identifies what is not clinically evident, as early as possible in the patient trajectory."

Joshua Tamayo-Sarver, MD PhD FACEP

Vice President of Innovation, Vituity
Emergency Physician and Biostatistician
Good Samaritan Hospital, CA


"Having worked on novel biomarkers for decades, I am genuinely impressed and excited about Biocogniv’s ability to leverage routine blood tests to detect acute conditions before they become obvious. Biocogniv's aiMarkers could soon become part of the standard of care in emergency medicine."

W. Frank Peacock, MD FACEP FACC

Thought leader in acute care biomarkers
Vice Chair, Emergency Medicine Research
Baylor College of Medicine

Unlock the value of your laboratory data today.